Old and new drugs in systemic therapy of pancreatic cancer
- 29 February 2004
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 49 (2), 135-151
- https://doi.org/10.1016/s1040-8428(03)00170-7
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Neoadjuvant radiotherapy: drugs or rays? Hypo- or hyper-?European Journal of Cancer, 2001
- Outcomes trial demonstrating a survival advantage of initial chemoradiotherapy for regional pancreatic adenocarcinoma (PCa)European Journal of Cancer, 2001
- ESPAC-1: A European, randomised study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancerEuropean Journal of Cancer, 2001
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival DurationAnnals of Surgical Oncology, 2001
- A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinomaEuropean Journal of Cancer, 2000
- Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamoleJournal of Gastrointestinal Surgery, 1998
- 1239: Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and peri-ampullary region: A phase III trial of the EORTC GITCCGEuropean Journal of Cancer, 1997
- National Patterns of Care for Pancreatic CancerAnnals of Surgery, 1996
- Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater—results of a controlled, prospective, randomised multicentre studyEuropean Journal of Cancer, 1993
- Chemotherapy in pancreatic cancerAnti-Cancer Drugs, 1991